ORIGINAL RESEARCH
Published on 12 Sep 2025
Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis
doi 10.3389/fphar.2025.1616826
- 1,128 views